SCHEMBL6450193

SCHEMBL6450193

CS(=O)(=O)c1ccc(C(=O)O)cc1[N+](=O)[O-].CSc1ccc(C(=O)O)cc1[N+](=O)[O-]

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 1/20 0.59
APEX1 P27695 1/20 0.53
POLB P06746 1/20 0.52
HCAR3 P49019 3/20 0.50
TSHR P16473 2/20 0.50
CASP6 P55212 1/20 0.50
THRA P10827 3/20 0.48
THRB P10828 5/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530451 0.89 VCAM1 (0.71) VCAM1POLBHCAR3TSHRCASP6
SCHEMBL3866808 0.88 APEX1 (0.66) APEX1POLBHCAR3TSHRCASP6
SCHEMBL6450195 0.88 VCAM1 (0.67) VCAM1POLBTHRBMEN1KMT2A
SCHEMBL7895159 0.82 APEX1 (0.53) APEX1POLBHCAR3TSHRCASP6
SCHEMBL18113472 0.78 CASP6 (0.62) VCAM1POLBHCAR3TSHRCASP6
SCHEMBL9185447 0.76 CASP6 (0.64) VCAM1APEX1POLBHCAR3TSHR
SCHEMBL11680786 0.76 CASP6 (0.64) APEX1POLBHCAR3TSHRCASP6
SCHEMBL1025382 0.76 APEX1 (0.69) APEX1POLBHCAR3TSHRCASP6
SCHEMBL9499862 0.75 POLB (0.59) VCAM1POLBHCAR3TSHRCASP6
SCHEMBL6003204 0.75 POLB (0.62) VCAM1APEX1POLBHCAR3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565446-A1 CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-08-24 EP disclosed
WO-2004048343-A1 CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-06-10 WO disclosed